Medication Safety

Wegovy Side Effects: Common, Serious, and How to Manage Them

The most common Wegovy (semaglutide 2.4 mg) side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal pain. Per the FDA label they are usually mild to moderate and ease with slow dose escalation. Serious risks include pancreatitis, gallbladder disease, and a boxed warning for thyroid C-cell tumors; the label also advises monitoring for depression or suicidal thoughts. Discuss persistent or severe symptoms with your prescriber.

Side Effects at a Glance

Common / Manageable

NauseaThe most common reaction; usually worst right after a dose increase and improves over time.
DiarrheaCommon, particularly early in treatment.
VomitingReported in trials; more likely at higher doses or after large meals.
ConstipationCommon; linked to slowed gastric emptying.
Abdominal painOften mild; persistent or severe pain should be reported.
Headache, fatigue, and dyspepsiaReported among the more common reactions in the weight-management trials.

Serious / Rare

Thyroid C-cell tumors (boxed warning)Seen in rodents; contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Human risk is undetermined.
PancreatitisAcute pancreatitis has been reported; severe, persistent abdominal pain warrants prompt evaluation.
Gallbladder diseaseCholelithiasis and acute gallbladder disease occurred more often with Wegovy than placebo in trials, partly related to rapid weight loss.
Depression / suicidal thoughtsThe label advises monitoring for depression, mood changes, or suicidal ideation, and to seek care if they occur.
Acute kidney injuryDehydration from vomiting/diarrhea can worsen kidney function; hydration is important.
Increased heart rateA mean increase in resting heart rate was observed; the label advises monitoring.
HypoglycemiaRisk increases in people with type 2 diabetes, especially with insulin or a sulfonylurea.
Hypersensitivity reactionsSerious allergic reactions including anaphylaxis and angioedema have been reported.

Why these side effects happen

Wegovy is the higher-dose (2.4 mg) semaglutide approved for chronic weight management. As a GLP-1 receptor agonist it slows gastric emptying and reduces appetite, which is what drives most of the gastrointestinal effects. The FDA-approved schedule escalates the dose over about 16 to 20 weeks specifically to limit nausea and other GI symptoms. This is educational; your prescriber sets your actual schedule.

Managing common side effects

Label-consistent strategies many people and clinicians use to reduce GI symptoms are below. They do not replace medical advice, and severe or persistent symptoms should be reported to your prescriber.

Eat smaller meals and stop at the first sign of fullness.
Limit fried and very fatty foods, which commonly worsen nausea.
Prioritize fluids if you have vomiting or diarrhea to protect kidney function.
Follow the prescribed titration; do not escalate faster than directed.
Report mood changes, severe abdominal pain, or signs of a gallbladder attack promptly.

When to call your prescriber

Get prompt care for severe, persistent abdominal pain (possible pancreatitis or gallbladder attack), any new or worsening depression or thoughts of self-harm, signs of an allergic reaction, or persistent vomiting with dehydration. Do not start, stop, or change your dose without consulting the clinician who prescribed it.

The Centurion companion approach

Centurion Coach is designed to work alongside a prescribed weight-management medication like Wegovy, never to replace it or your clinician. The companion role is twofold: helping you log symptoms against your dose so patterns are visible to you and your prescriber, and supporting muscle. Because significant weight loss can include lean muscle, Centurion emphasizes protein targets and resistance training to help preserve muscle while you lose fat. This is general education — it does not treat side effects, and medical decisions stay with your prescriber.

Medical Disclaimer

This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. Individual results may vary.

FAQ

Frequently Asked Questions

Per the FDA label, the most common adverse reactions are gastrointestinal — nausea is the most frequent, followed by diarrhea, vomiting, constipation, and abdominal pain. These are usually mild to moderate and ease as the dose is escalated slowly.

The label lists gallbladder disease, including gallstones, as a risk; it occurred more often with Wegovy than placebo in trials and is partly linked to rapid weight loss. Report severe upper-right abdominal pain, fever, or yellowing of the skin to your prescriber promptly.

The prescribing information advises monitoring for depression, mood changes, or suicidal thoughts during treatment. If you notice any of these, contact your healthcare provider right away.

For most people GI side effects are most noticeable after starting and after each dose increase, then improve over days to weeks as the body adjusts. The slow titration schedule is designed to reduce them. Tell your prescriber if symptoms are severe or persistent.

Common, label-consistent approaches include eating smaller meals, limiting high-fat foods, staying well hydrated, and following the prescribed titration rather than escalating quickly. These steps do not replace medical advice; report severe or persistent symptoms to your prescriber.

Sources

Wegovy (semaglutide) injection — Prescribing Information — FDA / DailyMed
AGA Clinical Guidance: management of patients taking GLP-1 receptor agonists — American Gastroenterological Association

Reviewed for accuracy by the Centurion Metrics Clinical Team. Last reviewed June 15, 2026. Content is sourced from FDA prescribing information and major clinical bodies.